

CALGP - Pankreas- und Gallenblase/-wege-Studien

Akronym	Studienart/-Phasen	Titel	Förderung / Kooperationen	Informationen	Ansprechpartner
Bereits laufend:					
PANDA-Studie	RCT	Pancreatoduodenectomy With or Without Ligamentum Teres Wrap Around Gastroduodenal Artery Stump for Prevention of Pancreatic Hemorrhage	keine	https://clinicaltrials.gov/ct2/show/NCT02588066?term=welsch&rank=2	Prof. J. Weitz, Dresden
PANCALYZE	prospektive Gewebebank	Evaluation molekularer Marker zur Abschätzung der Lokalisation eines Tumorrezidivs und der Prognose beim duktalem Adenokarzinom des Pankreas	keine	Deutschen Register Klinischer Studien DRKS00006179	Prof. Dr. C. Bruns, Köln
NEONAX	RCT	Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO Pancreatic Cancer Group	AIO-PAK-0313	https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5183-y	Prof. Dr. T. Seufferlein, Ulm
CONKO-07	LAPAC/RCT	Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer -a Randomized Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone		Trial registration EudraCT:2009-014476-21 (2013-02-22) and NCT01827553 (2013-04-09)	Prof. Dr. R. Fietkau, Erlangen
LAP07	LAPAC/RCT	Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery	GERCOR - Multidisciplinary Oncology Cooperative Group	https://clinicaltrials.gov/ct2/show/NCT00634725	Pascal Hammel, MD, PhD Hopital Beaujon

CALGP - Pankreas- und Gallenblase/-wege-Studien

<u>Anstehende Studien:</u>					
PyloResPres	RCT	Pylorusresektion versus Pyloruserhalt bei der Pankreatikoduodenektomie	DFG / DGAV & StuDoQ	https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-44	Prof. J. Werner, München
PS-PROM	prospektive Observationsstudie	Patient Reported Outcome Measurement in Pancreatic Surgery (PS-PROM) - A prospective observational cohort study	keine		Prof. T. Keck, Frau Dr. L. Bolm, Kiel
ESPAC-6	RCT	An open labelled phase III adjuvant trial of disease free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature	BMBF-Antrag		Prof. M. Büchler, Prof. J. Neoptolemos, Prof. T. Seufferlein, Heidelberg/Ulm
ESPAC-7	RCT	An open labelled phase II trial of resection rates in patients following induction chemotherapy with locally advanced unresectable pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature	BMBF-Antrag		Prof. M. Büchler, Prof. J. Neoptolemos, Prof. T. Seufferlein, Heidelberg/Ulm

CALGP - Pankreas- und Gallenblase/-wege-Studien

TRIANGLE trial	RCT	Conventional partial pancreatoduodenectomy versus an extended pancreatoduodenectomy (triangle operation) for pancreatic head cancers – the randomized controlled TRIANGLE trial	Förderung beim belgischen Anticancer Fund (ACF) beantragt, ? 1.000.- €/Fallhonorar		Prof. Dr. T. Hackert, Heidelberg
-----------------------	-----	--	--	--	---

GAIN Studie	Phase III, two-arm, multi-center, open label study	Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR)	DFG-Förderung EudraCT 2017-004444-38 DFG Projektnummer 316590476	https://gallenblase-register.com/2017/10/16/gain-studie/	PD Dr. med Thorsten Götze, Krankenhaus Nordwest Frankfurt; Telefon: +49 69 7601 4187, Fax: +49 69 7601 3655, Mail: Goetze.ThorstenOliver[at]khnw.de